SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " hims & hers " 71 found 🔀 AI-powered Shuffle
Hims & Hers Health (HIMS) Dropped, So What Is Driving Attention Now?
Hims & Hers Health (HIMS) is back in focus after fresh product news, with Hers Hair now rolling out in the UK as a clinician-led subscription hair loss service for women. Recent price action tells a mixed story for Hims & Hers Health, with the share price down 4.46% over the last day and 9.22% over the past week, yet roughly flat over one month and weaker year to date. The 1-year total shareholder return has declined 43.61%, while the 3-year total shareholder return is very large at roughly...
What Does Hims & Hers Health (HIMS) Expansion Into The UK And Australia Mean?
Hims & Hers Health (NYSE:HIMS) announced the launch of Hers personalised hair loss and wellness care in the UK in October 2026. The Hers UK rollout introduces tailored treatment plans for women's hair loss alongside broader wellness services through the company's telehealth platform. The business is also expanding its Hers care platform into Australia, adding another English speaking market to its international footprint. The Hers UK hair loss launch and Australia expansion open new chapters...
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Hims & Hers Health (HIMS) A Bargain After The Fraud Lawsuit Claims?
Hims & Hers Health (HIMS) is back in focus after a proposed securities fraud class action accused the telehealth provider of misleading investors about data sharing practices and prescription billing workflows. Recent price action for Hims & Hers Health has been choppy, with the share price slipping about 1% over the past day and week, climbing 4.7% over the past month, yet falling 24.2% across 90 days. The 1-year total shareholder return is down 44.8%, despite a very large 3-year gain that...
Hims And Hers Health (HIMS) Stock Looks Discounted After Its 368% Three Year Run
Hims & Hers Health has been a volatile ride, with long term shareholders seeing very large gains while more recent buyers have faced sharp pullbacks. That puts fresh attention on whether the current price lines up with what the business is actually generating in sales. With that backdrop, the question for anyone looking at Hims & Hers Health today is how much of those expectations are already built into the share price. Over the past 3 years, Hims & Hers Health has delivered a share price...
Hims & Hers Health (HIMS) Unveils AI Native Weight Loss Care Platform
Hims & Hers Health (NYSE:HIMS) introduced an AI native weight loss care platform built around a closed loop clinical system. The new offering uses continuous learning, real time monitoring, and automation to support clinician decisions within the weight loss program. Management positions the platform as a way to scale weight management services while aiming to keep safety controls embedded in workflows. The AI native weight loss care launch matters, but investors also need to weigh other...
Hims & Hers Health, Inc. (HIMS) Investors: November 2, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Did you buy HIMS securities between August 4, 2025 and July 29, 2026? Affected HIMS Investor Summary Who: Hims & Hers Health, Inc. (NYSE: HIMS) What:...
Telehealth companies keep exposing customers' medical data. What should they do?
The FTC recently filed a lawsuit alleging Hims & Hers secretly exposed customers’ health data and signed them up for hard-to-cancel subscriptions without permission. It's the latest in a series of similar cases.
Telehealth companies keep exposing their customers' medical data. What should they do?
The Federal Trade Commission recently filed a lawsuit alleging that telehealth company Hims & Hers secretly exposed customers’ health data.
I'm Calling It: Hims & Hers Health Will Soar 56% by the End of 2026
Hims & Hers Health is still growing rapidly, but whether that growth can translate into better economics could determine how much further the stock can climb.
I'm Calling It: Hims & Hers Health Will Soar 56% by the End of 2026
Hims & Hers Health is still growing rapidly, but whether that growth can translate into better economics could determine how much further the stock can climb.
Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know
The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $28.17, representing a +1.66% change from its previous close.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS
/PRNewswire/ -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's...
INVESTOR DEADLINE ALERT: Hims & Hers Health, Inc. (HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Did you buy HIMS securities between August 4, 2025 and July 29, 2026? Affected HIMS Investor Summary Who: Hims & Hers Health, Inc. (NYSE: HIMS) What:...
Hims & Hers offers GLP-1 weight-loss drugs, men's health treatments in Australia
Telehealth company Hims & Hers said on Monday it has begun offering branded GLP-1 weight-loss drugs and other treatments to men in Australia as it continues to expand its international business.
Why Hims & Hers Health (HIMS) Stock Is Nosediving
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 9.2% in the afternoon session after Bloomberg reported that Visa enrolled the telehealth company in its Acquirer Monitoring Program following a surge in customer credit card disputes in its weight-loss subscription business.
5 Revealing Analyst Questions From Hims & Hers Health’s Q2 Earnings Call
Hims & Hers Health’s second quarter results were driven by strong subscriber growth and a ramp-up in its branded weight loss offerings, yet the market reacte...
Archer Aviation Exec Says Boeing Deal Will ‘Significantly Change the Profile’ as $200 Million Insitu Business Joins Portfolio
Archer Aviation Inc.‘s (NYSE:ACHR) deal with Boeing Co. (NYSE:BA) could significantly reshape the electric vertical take-off and landing (eVTOL) company. Insitu’s $200 Million Revenue Business During the company’s second-quarter earnings call on Monday, Archer’s Chief Financial Officer Priya Gupta hailed the company’s acquisition of unmanned aircraft systems manufacturer Insitu, as well as autonomous eVTOL maker Wisk Aero and SkyGrid in an all-stock deal. Read Also: Rocket Lab USA, Hims & Hers,
Hims & Hers Health (NYSE:HIMS) Exceeds Q2 CY2026 Expectations But Stock Drops
Telehealth company Hims & Hers Health (NYSE:HIMS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 38.2% year on year to $753.2 million. On top of that, next quarter’s revenue guidance ($890 million at the midpoint) was surprisingly good and 12.4% above what analysts were expecting. Its GAAP loss of $0.37 per share was significantly below analysts’ consensus estimates.
San Francisco’s Hims & Hers sued over customer privacy, subscriptions
Federal and state regulators sued San Francisco-based Hims & Hers, alleging deceptive prescription billing, difficult cancellations and the improper sharing of sensitive health information.
FTC Sues Hims & Hers Over Health Privacy And Billing Practices
By Ellyn Vohnoutka HealthDay ReporterFRIDAY, July 31, 2026 (HealthDay News) — The U.S. Federal Trade Commission (FTC) has sued telehealth company Hims & Hers, alleging it shared consumers' private health information with advertising platforms and unknowingly charged some customers for ...
Utah joins FTC in lawsuit accusing Hims & Hers of sharing sensitive health information
Utah has joined the Federal Trade Commission and California in a lawsuit accusing telehealth company Hims & Hers of sharing consumers’ sensitive health informat
Hims & Hers sued over sending users health info to social media platforms
Digital telehealth platform Hims & Hers is facing a civil lawsuit over accusations of sending users’ health information to online advertisers after promising privacy.
FTC sues Hims & Hers, alleging it shared people's health data with Meta and Snap
Telehealth platform disclosed users' "most private" health info and locked consumers into subscriptions, regulators allege.
Hims misled consumers and violated their privacy, FTC alleges in a lawsuit
The U.S. Federal Trade Commission sued telehealth company Hims & Hers alleging business practices that agency says mislead consumers.
US FTC suing Hims & Hers for sending user health info to Meta, Snap
The U.S. Federal Trade Commission is suing Hims & Hers alleging the telehealth platform shared users' health data with online advertisers despite promising privacy and engaged in deceptive billing and cancellation practices, an FTC spokesperson said.
Living Longer Is Big Business. These Stocks Will Benefit.
Longevity healthcare could be big business for companies like Planet Fitness, Abbott, and Hims & Hers.
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now?
Is HIMS a good stock to buy? We came across a bearish thesis on Hims & Hers Health, Inc. on Valueinvestorsclub.com by Pridwen. In this article, we will summarize the bears’ thesis on HIMS. Hims & Hers Health, Inc.’s share was trading at $27.51 as of June 2nd. HIMS’s trailing and forward P/E were 57.14 and 58.82 […]
Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health Platform
The acquisition extends the company's leadership position across Australia, Canada, Germany, Japan, and the United Kingdom, with the scale to redefine healthcare for hundreds of millions of people Hims Hers Health, Inc. (NYSE: HIMS) has completed its acquisition of Eucalyptus, advancing its position as the world's largest consumer health platform. Building on the earlier acquisitions of ZAVA and Livewell , Hims Hers now has a leading presence across the US, UK, Australian, and Canadi
Hims & Hers CEO is plotting new ways to upend traditional health care
Hims & Hers built massive weight-loss markets using telehealth. Peptides, if authorized by the FDA, stand to become a major part of the company’s shift to wellness and longevity.
Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
Proceeds intended to be used to preserve financial flexibility as Hims Hers executes on its international expansion strategy, including the proposed acquisition of Eucalyptus, invests in technology and operational infrastructure to drive anticipated cost efficiencies, and enhances the consumer experience with AI and its closed-loop data ecosystem. Hims Hers Health, Inc. (“Hims Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Hims Hers also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an
Stocks making the biggest moves after hours: Hims & Hers, Gitlab, Cleanspark, Webtoon Entertainment & more
See which stocks are posting big moves after the bell.
Hims & Hers Health Swings to First-Quarter Loss as Expenses Rise
The telehealth platform posted a quarterly loss of $92.1 million, offsetting a 4% increase in revenue.
Hims & Hers raises 2026 revenue forecast on strong demand for personalized care
Hims & Hers Health raised its 2026 revenue forecast on Monday, betting on increased sales for its personalized healthcare offerings.
Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results
SAN FRANCISCO, May 11, 2026--Hims & Hers Health, Inc. ("Hims & Hers" or the "Company", NYSE: HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2026. Moving forward, the Company plans to transition to an annual rather than quarterly shareholder letter and will continue to provide regular updates through a quarterly earnings call, earnings release, and supplemental materials.
GoodRx vs. Hims & Hers Health: Stagnation vs. Growth in Revenue
Quarterly filings reveal markedly different revenue trajectories and margin profiles for these two healthcare platforms. What do their latest numbers indicate?
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now?
Is HIMS a good stock to buy? We came across a bullish thesis on Hims & Hers Health, Inc. on Investment Ideas by Antonio’s Substack by Antonio Linares. In this article, we will summarize the bulls’ thesis on HIMS. Hims & Hers Health, Inc.’s share was trading at $29.76 as of April 21st. HIMS’s trailing and forward […]
RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
Hims may have an chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and patented drugs.
Asset Manager Exits Shares of Hims & Hers Health
Hims & Hers Health has struggled, but it just inked a new partnership with Novo Nordisk.
Introducing Hims & Hers Benefits, Unlocking Health & Wellness Discounts for Subscribers
The program debuts with Prenuvo and Eight Sleep, providing discounts on advanced diagnostics and sleep technology Hims Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Hims Hers Benefits, a new way for subscribers to access the best innovations in whole body health. This new initiative provides active subscribers access to discounts from health partners, all in one place, including whole body MRI scans from Prenuvo and adaptive bed systems from Eight Sleep. This is just the beginning of a larger benefits program that will make comprehensive, holistic care more accessible and affordable for subscribers. “True health doesn’t happen in a vacuum. It’s the result of the data you gather, the insights you can access, and the daily choices you make,” said Dheerja Kaur, Chief Product Officer at Hims Hers. “By leveraging our scale, we’re bringing health and wellness innovations like Prenuvo’s whole body MRI scans and Eight Sleep’s
Stock Market Today, March 9: Hims & Hers Health Soars on Novo Nordisk Weight-Loss Drug Deal
On March 9, 2026, a new Novo Nordisk pact reshaped this telehealth player’s GLP-1 strategy, margins, and legal risk profile.
Health Care Roundup: Market Talk
Find insights on Roche’s breast-cancer drug, the partnership between Hims & Hers and Novo Nordisk and more in the latest Market Talks from the health-care sector.
Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration
Hims & Hers Health has agreed to stop selling compound versions of Novo Nordisk's Wegovy and other weight-loss drugs, ending a patent lawsuit for now.
Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight los…
Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss medicines sold through the Hims platform.
Hims & Hers Health and Novo Nordisk End Lawsuit Over Weight Loss Medications, Enter Collaboration
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss medicines sold through the Hims platform. Shares of Hims & Hers Health Inc. jumped more than 40% in ...
Hims & Hers Announces Strategic Shift for US Weight Loss Business
Starting with a new collaboration with Novo Nordisk, the company announced plans to align its US and global strategies with a focus on an increasing variety of FDA-approved GLP-1s Hims Hers Health, Inc. (NYSE: HIMS) today announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s, evolving its US offering to match the company’s approach globally. In the US, the company now plans to provide GLP-1 customers with access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale. By aligning its domestic and international models in weight loss, Hims Hers will become the largest global consumer health platform for access to more affordable, approved medications. The US weight loss landscape has transformed dramatically since Hims Hers entered the market in 2023. Progress in the industry has made a broader range of FDA-approved GLP-1 treatments
Stocks making the biggest moves premarket: Hims & Hers Health, oil stocks, Live Nation Entertainment & more
These are the stocks posting the largest moves in premarket trading.
Hims expansion may not come in time for risky GLP-1 business
Telehealth company Hims & Hers Health , known for its weight-loss drug business, is promising it can diversify away from its reliance on compounded GLP-1 sales in the U.S., but that may not happen soon enough for investors who are growing impatient.
In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding
In earnings call, Hims & Hers CEO Andrew Dudum addressed the increased scrutiny on compounded GLP-1s and its impact on the business’s bottom line.
Hims & Hers Health Fourth-Quarter Profit Falls Despite Higher Revenue
The telehealth platform posted a quarterly profit of $20.6 million, down from $26 million a year earlier.
Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims Hers Health, Inc. (“Hims Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. “More than 2.5 million subscribers now rely on us for a healthcare experience that is both accessible and deeply personal – and we believe we’re well on our way to becoming the global leader in consumer health,” said Andrew Dudum, co-founder and CEO. “In 2025, we made it possible for more customers across the world to depend on us
What To Expect From Hims & Hers Health’s (HIMS) Q4 Earnings
Telehealth company Hims & Hers Health (NYSE:HIMS) will be announcing earnings results this Monday after market close. Here’s what to look for.
Hims & Hers Health to acquire Australia's Eucalyptus for up to $1.15 billion
The deal would give Hims & Hers a foothold in Australia and Japan while deepening its presence in the United Kingdom, Germany, and Canada.
Hims & Hers Health to acquire Australia's Eucalyptus for up to $1.15 billion
Hims & Hers Health said on Thursday it will acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion, as the U.S. telehealth platform seeks to broaden its personalized care business into new international markets.
Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform
Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company’s ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structured to preserve the financial flexibility of the company, ensuring continued control over balance sheet management and capital allocation. As its US business continues to grow, Hims Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and
Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows
Hedge fund bets against Hims & Hers Health hit their highest in at least a year in January, just before the online telehealth firm clashed with Novo Nordisk over its cut-price weight-loss pill, according to data shared with Reuters by Hazeltree.
Stocks making the biggest moves premarket: Oracle, Novo Nordisk, Hims & Hers Health, Kroger and more
These are the stocks posting the largest moves in premarket trading.
GLP-1 Envy Was Just the Beginning
A Super Bowl ad by Hims & Hers sells the idea that everyone should want to be billionaire-healthy.
Hims & Hers responds to FDA pressure, pulls knockoff Wegovy drug launch after regulatory threats
Telehealth company Hims & Hers cancels $49 monthly weight loss drug launch following FDA warnings about unapproved semaglutide compounds and Novo threats.
Hims & Hers stops selling weight loss pill days after unveiling it
Hims & Hers said it would stop selling its new compounded semaglutide pill after "constructive conversations with stakeholders across the industry."
Hims & Hers will stop selling compounded version of Novo’s obesity pill
Hims & Hers will stop selling what it claims to be a cheaper, compounded version of Novo Nordisk's obesity pill on its telehealth platform.
Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown
Hims & Hers said in a statement on Saturday that it will stop offering access to the compounded semaglutide pill after the U.S. Food and Drug Administration said it would take action against the telehealth provider for its $49 weight-loss pill.
Health Regulators Ask DOJ to Investigate Hims & Hers. The Stock Plunges.
The Department of Health and Human Services referred the consumer wellness company to the Department of Justice for investigation, wrote HHS general counsel Mike Stuart in a post on X Friday afternoon.
Health Agency Refers Knockoff GLP-1 Provider Hims & Hers to Justice Department
The FDA said it would take “decisive steps” to restrict nonapproved drugs that use GLP-1 active pharmaceutical ingredients.
VIEW Hims and Hers Health's compounded Wegovy pill offering fuels market jitters
Hims & Hers said it would begin offering compounded versions of Novo Nordisk's Wegovy pill at an introductory price of $49 per month.
Hims & Hers Super Bowl Ad To Spotlight The Health-Wealth Gap
Narrated by Common, HIms and Hers' 2026 Super Bowl ad highlights how income disparities shape health outcomes—and position affordability as part of the solution.
Why Hims & Hers Health (HIMS) Is Down 6.8% After Amazon Pharmacy Adds Wegovy Weight-Loss Pill
In recent days, Amazon Pharmacy announced it would begin offering Novo Nordisk’s Wegovy once-daily weight-loss pill through both insurance and cash-pay channels, including future availability via its pharmacy kiosks. This move directly targets the fast-growing weight management segment where Hims & Hers Health participates, raising fresh questions about how differentiated and resilient its broader telehealth platform and recurring-care model really are beyond GLP-1 offerings. We’ll now...
Hims & Hers to Acquire YourBio Health, Pioneer Behind Advanced, Pain-Free Blood Sampling Technology
Acquisition Combines Hims Hers’ Leading Wellness Platform with YourBio’s Patented, Virtually Painless Micro-Needle Technology to Redefine the Future of Blood Sampling Hims Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced that it has entered into a definitive agreement to acquire YourBio Health, Inc., a Boston-based pioneer in capillary whole blood sampling technology. Powered by YourBio’s advanced blood sampling devices, the acquisition will help accelerate efforts to redefine and modernize the overall blood collection experience, making pain-free blood sampling the new standard. YourBio Health develops technologies designed to simplify the process and expand when, where, and how blood samples can be collected—including beyond traditional clinic settings. Its TAP® device, built on HALO™ technology, uses bladeless microneedles thinner than an eyelash to produce high-quality capillary blood samples in seconds, without the pain or